

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
MARGARET FORNEY PRESCOTT  
APPLICATION NO: 10/531,677  
FILED: APRIL 15, 2005

Art Unit: 1611  
Examiner: Kudla, Joseph S.

FOR: BISPHOSPHONATES FOR THE TREATMENT OF  
ATHEROSCLEROSIS AND DEVICES COMPRISING THEM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 101  
East Hanover, NJ 07936-1080  
(862) 778-7852  
Date: 3/18/07

  
Oona A. Manzari  
Attorney for Applicant  
Reg. No. 48,152



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
MARGARET FORNEY PRESCOTT  
INTERNATIONAL APPLICATION NO: PCT/EP/0311379  
FILED: 14 OCTOBER 2003  
U.S. APPLICATION NO: 10/531,677  
35 USC §371 DATE: 15 APRIL 2005  
FOR: BISPHOSPHONATES FOR THE TREATMENT OF  
ATHEROSCLEROSIS AND DEVICES COMPRISING THEM

Art Unit: 1611  
Examiner: Kudla, Joseph S.

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed June 26, 2008. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.



The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 101  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
\_\_\_\_\_  
Oona A. Manzari  
Attorney for Applicant  
Reg. No. 48,152

Date: 3/18/09